Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

But this seems to have saved shareholders some money, didn't it?
"In March 2018, Protagonist announced discontinuation of the study following a planned interim analysis conducted by an independent Data Monitoring Committee (DMC). The interim data revealed an unusually high placebo rate of clinical remission (24 percent, approximately four times higher than historical norms for similar UC studies) that led to a futility decision and discontinuation of the trial."

Would have been interesting to know whether the interim analysis of Prurisol could have done the same thing.

Maybe I missed the point.